Latest in Cardiology from ACC.org

• ATTR-CM: Sex Differences, Delayed Diagnosis and Effect of Acoramidis
  Three recent studies, two published in JACC: Advances and a third published in JAMA Cardiology, investigate sex differences, delayed diagnosis and the effect of acoramidis on heart failure (HF)-related health status in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
• ADVANCE OUTCOMES: Ralinepag Reduces Clinical Worsening For PAH
  Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet.
• PARTNER 3: 7-Year TAVR vs. SAVR Outcomes in Low-Risk Patients
  Both TAVR and SAVR were associated with a sustained, substantial improvement in patient-reported health status among patients with severe aortic stenosis (AS) considered at low risk, according to the seven-year outcomes of the PARTNER 3 trial published July 29 in JACC.
• JACC CKM Guideline Spotlight Issue Addresses Obesity, HF Prevention, More
  The recent release of the 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome marked an important step in defining evidence-based approaches to CKM prevention, risk assessment and treatment.
• Cardiogenic Shock and Mechanical Circulatory Support: Year in Review 2025
  The year 2025 was a landmark year for cardiogenic shock (CS) and mechanical circulatory support (MCS). Two major clinical guideline documents were published, the longest-duration follow-up data from the field's pivotal trial were released, and real-world registries continued to challenge trial generalizability.